Virginia Commonwealth University School of Medicine, 1201 E Marshall St #4-100, Richmond, VA 23298, United States.
Department of Neurology, Virginia Commonwealth University School of Medicine, 417N 11th St, Richmond, VA 23298, United States.
Neuromuscul Disord. 2024 Jun;39:48-53. doi: 10.1016/j.nmd.2024.04.008. Epub 2024 Apr 29.
Limb girdle muscular dystrophy (LGMD) is a debilitating disease and the fourth most common muscular dystrophy. This study describes the development of the LGMD-Health Index (LGMD-HI). Participants were aged >18 years and recruited from three LGMD registries and GRASP-LGMD consortium. The initial instrument, comprised of 16 thematic subscales and 161 items, underwent expert review resulting in item removal as well as confirmatory factor analysis followed by inter-rater reliability and internal consistency of the subscales. Following expert review, one subscale and 59 items were eliminated. Inter-rater reliability was assessed and five items were removed due to Cohen's kappa <0.5. The final subscales had high internal consistencies with an average Cronbach alpha of 0.92. Test re-test reliability of the final instrument was high (intraclass correlation coefficient=0.97). Known groups validity testing showed a statistically significant difference in LGMD-HI scores amongst subjects based on ambulation status (28.7 vs 50.0, p < 0.0001), but not sex, employment status, or genetic subtype. The final instrument is comprised of 15 subscales and 97 items. The LGMD-HI is a disease-specific, patient-reported outcome measure designed in compliance with published FDA guidelines. This instrument is capable of measuring burden of disease with no significant variation based on LGMD subtype.
肢带型肌营养不良症(LGMD)是一种使人虚弱的疾病,是第四种最常见的肌肉营养不良症。本研究描述了 LGMD-健康指数(LGMD-HI)的开发过程。参与者年龄大于 18 岁,从三个 LGMD 登记处和 GRASP-LGMD 联盟招募而来。最初的工具包括 16 个主题子量表和 161 个项目,经过专家审查,对项目进行了删除,并进行了验证性因素分析,随后评估了子量表的组内一致性和内部一致性。经过专家审查,一个子量表和 59 个项目被删除。评估了组内一致性,由于 Cohen's kappa<0.5,有 5 个项目被删除。最终子量表的内部一致性很高,平均 Cronbach alpha 为 0.92。最终工具的重测信度很高(组内相关系数=0.97)。基于不同的步行状态,对已知组别的有效性进行测试,结果显示 LGMD-HI 得分在患者之间存在统计学上的显著差异(28.7 分对 50.0 分,p<0.0001),但与性别、就业状况或遗传亚型无关。最终工具由 15 个子量表和 97 个项目组成。LGMD-HI 是一种特定于疾病的患者报告结局测量工具,符合已发布的 FDA 指南。该工具能够测量疾病负担,不会因 LGMD 亚型的不同而产生显著变化。